Stock PANG PANGAEA ONCOLOGY, S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Pangaea Oncology, S.A.

Equities

PANG

ES0105221008

Delayed BME
Other stock markets
 07:30:08 30/04/2024 pm IST 		5-day change 1st Jan Change
1.75 EUR -.--% Intraday chart for Pangaea Oncology, S.A. +1.16% -4.89%
2023 Pangaea Oncology, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
2023 Pangaea Oncology, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • With an enterprise value anticipated at 4.89 times the sales for the current fiscal year, the company turns out to be overvalued.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
PANGAEA ONCOLOGY, S.A. Stock Pangaea Oncology, S.A.
-4.89% 55.04M -
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.67% 42.4B
B
LONZA GROUP AG Stock Lonza Group AG
+46.11% 40.04B
A
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.55% 24.94B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.66% 18.96B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.96% 12.3B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.57% 11.95B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+16.03% 11.32B
B+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.80% 11.55B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PANG Stock
  4. Ratings Pangaea Oncology, S.A.